Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells

Laboratory of Immunology, National Institute on Aging, NIH, Baltimore, Maryland 21224, USA.
Journal of Clinical Investigation (Impact Factor: 13.77). 08/2004; 114(1):57-66. DOI: 10.1172/JCI21134
Source: PubMed

ABSTRACT Ghrelin, a recently described endogenous ligand for the growth hormone secretagogue receptor (GHS-R), is produced by stomach cells and is a potent circulating orexigen, controlling energy expenditure, adiposity, and growth hormone secretion. However, the functional role of ghrelin in regulation of immune responses remains undefined. Here we report that GHS-R and ghrelin are expressed in human T lymphocytes and monocytes, where ghrelin acts via GHS-R to specifically inhibit the expression of proinflammatory anorectic cytokines such as IL-1beta, IL-6, and TNF-alpha. Ghrelin led to a dose-dependent inhibition of leptin-induced cytokine expression, while leptin upregulated GHS-R expression on human T lymphocytes. These data suggest the existence of a reciprocal regulatory network by which ghrelin and leptin control immune cell activation and inflammation. Moreover, ghrelin also exerts potent anti-inflammatory effects and attenuates endotoxin-induced anorexia in a murine endotoxemia model. We believe this to be the first report demonstrating that ghrelin functions as a key signal, coupling the metabolic axis to the immune system, and supporting the potential use of ghrelin and GHS-R agonists in the management of disease-associated cachexia.

Download full-text


Available from: Daniel Dennis Taub, Jun 19, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease associated with accelerated atherosclerosis and increased risk of cardiovascular (CV) disease. AS patients also display a high prevalence of features clustered under the name of metabolic syndrome (MeS). Anti-TNF- α therapy was found to be effective to treat AS patients by suppressing inflammation and also improving endothelial function. Previously, it was demonstrated that a short infusion of anti-TNF- α monoclonal antibodyinfliximab induced a rapid and dramatic reduction in serum insulin levels and insulin resistance along with a rapid improvement of insulin sensitivity in nondiabetic AS patients. The role of adipokines, MeS-related biomarkers and biomarkers of endothelial cell activation and inflammation seem to be relevant in different chronic inflammatory diseases. However, its implication in AS has not been fully established. Therefore, in this review we summarize the recent advances in the study of the involvement of these molecules in CV disease or MeS in AS. The assessment of adipokines and biomarkers of endothelial cell activation and MeS may be of potential relevance in the stratification of the CV risk of patients with AS.
    03/2014; 2014:860651. DOI:10.1155/2014/860651
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic internal inflammation secondary to adiposity is a risk factor for sporadic breast cancer and Post-Menopausal Breast Cancer (PMBC) is largely defined as such. Adiposity is one of the clinical criteria for the diagnosis of Metabolic Syndrome (MetS) and is a risk factor for PMBC. We examined SNPs of eight genes implicated in adiposity, inflammation and cell proliferation in a Prospective-specimen-collection, Retrospective-Blinded-Evaluation (PRoBE) design approach. A total of 180 cases and 732 age-matched controls were identified from the MyCode prospective biobank database and then linked to the Clinical Decision Information System, an enterprise-wide data warehouse, to retrieve clinico-demographic data. Samples were analyzed in a core laboratory where the personnel were masked to their status. Results from multivariate logistic regression yielded one SNP (rs2922126) in the GHSR as protective against PMBC among homozygotes for the minor allele (A/A) (OR = 0.4, 95% CI 0.18-.89, P-value = .02); homozygosity for the minor allele (C/C) of the SNP (rs889312) of the gene MAP3K1 was associated with the risk of PMBC (OR = 2.41, 95% CI 1.25-4.63 P-value = .008). Advanced age was protective against PMBC (OR = 0.98, 95% CI 0.95-0.99, P-value = .02). Family history of breast cancer (OR = 2.22, 95% CI 1.14-4.43. P = .02), HRT (OR = 3.35; 95% CI 2.15-5.21, P < .001), and MetS (OR = 14.83, 95% CI 5.63-39.08, P < .001) and interaction between HRT and MetS (OR = 39.38, 95% CI 15.71-98.70, P < .001) were associated with the risk of PMBC. We did not detected significant interactions between SNPs or between the SNPs and the clinico-demographic risk factors. Our study further confirms that MetS increases the risk of PMBC and argues in favor of reducing exposure to HRT. Our findings are another confirmation that low penetrance genes involved in the inflammatory pathway, i.e. MAP3KI gene, may have a plausible causative role in PMBC. Given the fact that genetic constitutionality of individuals cannot be changed, efforts should be focused on life style modification.
    SpringerPlus 11/2013; 2:638. DOI:10.1186/2193-1801-2-638
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract In this randomized, double-blind, placebo-controlled trial, 80 lactating mothers were randomly divided into two groups to receive daily supplement of synbiotic (n = 40) or a placebo (n = 40) for 30 days. Information on dietary intake was collected and anthropometric measurements were taken using standard calibrated instruments. Data analysis was carried out using nutritionist IV, SPSS and Epi Info software. Synbiotic supplementation resulted in a slight increase in mean energy intake while, in the placebo group, maternal energy intake decreased significantly (p < 0.023). Although maternal weight and BMI increased slightly in the supplemented group, these two parameters decreased significantly in the placebo group (p < 0.01). Also, infants' weight gain in the synbiotic group was significantly higher than the placebo group after the intervention (p < 0.044). Synbiotics may prevent weight loss in lactating mothers and result in weight gain in infants. Further experiments are required to study these effects in undernourished lactating mothers and their infants.
    International Journal of Food Sciences and Nutrition 03/2013; 64(6). DOI:10.3109/09637486.2013.775229 · 1.20 Impact Factor